Breast cancer represents a heterogeneous group of human cancer at both histological and
molecular levels. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal …

Simple Summary Identification of mismatch repair-deficient tumors (MMRd), which occur in
up to 30% of all endometrial cancers (EC), has become unavoidable for therapeutic …

The landscape of diagnosing and treating endometrial cancer is undergoing a profound
transformation due to the integration of molecular analysis and innovative therapeutic …

Endometrial tumors show substantial heterogeneity in their immune microenvironment. This
heterogeneity could be used to improve the accuracy of current outcome prediction tools …

Abstract Programmed death-ligand 1 (PD-L1) is a biomarker that may predict the response
to anti-programmed death 1/PD-L1 immunotherapy. We evaluated the expression of PD-L1 …

Endometrial serous carcinoma (ESC) is an aggressive type of endometrial carcinoma with a
poor prognosis. Immune checkpoint blockade has evolved as a novel treatment option for …

Endometrial carcinoma (EC) is the most common gynecological malignant disease in high-
income countries, such as European countries and the USA. The 2020 edition of the World …

The prognosis of recurrent or metastatic endometrial cancer is poor, with five-year survival of
only 10–20%. First-line therapy consists of either platinum-based chemotherapy or …

Background Poorly differentiated endometrioid adenocarcinoma and serous
adenocarcinoma represent an aggressive subtype of endometrial cancer (EC). Programmed …

Abstract Objective PD-L1 and PD-1 are predictive markers for immunotherapy and
increasingly relevant in endometrial cancer. The reported fraction of positive primary tumors …